Tech Center 1600 • Art Units: 1634 1683
This examiner grants 47% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18300477 | Molecular Biomarkers for Predicting Patient Response to Steroid Therapy | Non-Final OA | Florida State University Research Foundation, Inc. |
| 17372113 | COMPOSITIONS AND METHODS RELATED TO DIFFERENTIALLY METHYLATED DNA SEQUENCES ASSOCIATED WITH MONOALLELIC GENE EXPRESSION AND DISEASE | Non-Final OA | North Carolina State University |
| 17794269 | AN EPIGENETIC CLOCK FOR GALLIFORMES | Final Rejection | EVONIK OPERATIONS GMBH |
| 18051488 | Association Of T Cell Leukemia/Lymphoma Protein 1A (TCL1A) With Clonal Hematopoiesis Of Indeterminate Potential (CHIP) | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17854283 | Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) Inhibitors | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17854412 | Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18007097 | BIOMARKER FOR DIAGNOSING NONALCOHOLIC STEATOHEPATITIS USING MICRORNA COMBINATION | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18042167 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18300253 | TUMOR ORGANOID CULTURE COMPOSITIONS, SYSTEMS, AND METHODS | Non-Final OA | Tempus AI, Inc. |
| 17813942 | DETECTION OF GENETIC VARIANTS | Final Rejection | BIO-RAD LABORATORIES, INC. |
| 17776822 | METHODS OF SYNTHESIZING RNA MOLECULES | Non-Final OA | BAYER HEALTHCARE LLC |
| 17920652 | METHOD FOR DETECTING SEVERITY OF PREMENSTRUAL SYNDROME | Non-Final OA | KAO CORPORATION |
| 18168955 | METHODS OF DETERMINING COVID-19 MORTALITY RISK | Non-Final OA | WASHINGTON UNIVERSITY |
| 17831103 | SYSTEMS AND METHODS FOR MULTIMODAL ANALYSIS OF SURGICAL DRAIN FLUID USING INTERCHANGEABLE AND CUSTOMIZABLE NUCLEIC ACID BASED TESTS | Final Rejection | Washington University |
| 17906123 | THERAPEUTIC METHODS FOR THE TREATMENT OF SUBJECTS WITH RISK ALELLES IN IL33 | Non-Final OA | MedImmune Limited |
| 17683656 | METHODS FOR PREDICTING ANTI-CANCER RESPONSE | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 17776424 | CHARACTERIZING MODULATORS OF ADAMTS-7 AND ADAMTS-12 | Non-Final OA | Bayer Aktiengesellschaft |
| 17926804 | EPIGENETIC MODIFICATION OF SELECT GENES AS MARKERS OF HYPERSOMNOLENCE | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17811995 | LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY | Final Rejection | Medizinische Hochschule Hannover |
| 18245957 | APPARATUS, KITS AND METHODS FOR PREDICTING THE DEVELOPMENT OF SEPSIS | Non-Final OA | The Secretary of State for Defence |
| 17796293 | Biomarkers for Risk Prediction of Parkinson's Disease | Final Rejection | SINGAPORE HEALTH SERVICES PTE LTD |
| 17788476 | Disease Detection in Liquid Biopsies | Final Rejection | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D |
| 18593639 | NON-INVASIVE PRENATAL TESTING AT EARLY STAGE OF PREGNANCY | Final Rejection | BillionToOne, Inc. |
| 18009625 | METHOD OF DIAGNOSING MITOCHONDRIAL DNA DISORDERS USING STOOL SAMPLES | Non-Final OA | University of Newcastle Upon Tyne |
| 17787433 | NOVEL DRUGGABLE TARGETS FOR THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND METHODS FOR DIAGNOSIS AND TREATMENT USING THE SAME | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17846157 | DIAGNOSIS OF FRONTOTEMPORAL DEMENTIA | Final Rejection | UCL Business Ltd |
| 17779936 | METHODS AND COMPOSITIONS FOR ANALYSES OF CANCER | Non-Final OA | Stichting Vumc |
| 17801979 | METHOD FOR SELECTING NORMALIZING GENES FOR COPY NUMBER VARIATION DETECTION AND COMPOSITION FOR DETECTING C-MET COPY NUMBER VARIATION SELECTED BY METHOD | Non-Final OA | ABION INC. |
| 17734708 | METHODS OF TREATING LIPEDEMA INCLUDING AKR1C1 AS A THERAPEUTIC TARGET | Non-Final OA | MAGI EUREGIO SCS |
| 18022000 | METHOD OF PROGNOSING PREECLAMPSIA | Non-Final OA | University of Tartu |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy